The Brain You’ll Have at 70 Is Being Built Right Now

Somewhere in the research on cognitive decline, there is a fact that stops most people in their tracks.

The brain changes associated with Alzheimer’s disease — the amyloid plaques, the tau tangles, the progressive loss of synaptic connections — begin accumulating fifteen to twenty years before any symptoms appear. By the time someone notices that their memory is not what it was, the process has been underway since they were in their forties or fifties.

This is not a counsel of despair. It is, if you choose to read it this way, an extraordinary opportunity. Because it means that the decisions you are making right now — about what you eat, how you sleep, how you manage stress, how much you move — are not just about how you feel this week. They are shaping the brain you will be living in at seventy.

Yesterday’s post looked at the Harvard JAMA Neurology study that tracked 159,347 people for up to 28 years and found that dietary quality in the 45–54 age window showed the strongest association with cognitive outcomes later in life. Today I want to go deeper — into what that brain actually looks like at seventy if you get this right, and what the emerging science says about the levers available to you now.

What a well-functioning brain at seventy looks like

Cognitive decline is not inevitable. This is one of the most important reframes in contemporary neuroscience, and it is still not widely understood outside research circles.

The brain has remarkable neuroplasticity — the capacity to form new connections, maintain existing ones, and adapt to damage — well into later life. Studies of so-called “SuperAgers” — individuals in their seventies and eighties whose cognitive function matches that of people twenty to thirty years younger — have identified a consistent set of characteristics: lower neuroinflammation, better metabolic health, higher levels of BDNF (brain-derived neurotrophic factor), more diverse gut microbiomes, and sustained engagement with intellectually demanding activities.

None of these are fixed traits. They are outcomes. And the inputs that produce them — the dietary patterns, the sleep quality, the stress regulation, the physical activity — are largely the same inputs that the methylation and biological age research has been converging on for the past decade.

The Bredesen evidence: what happens when you treat the root causes

In December 2025, Dr Dale Bredesen and colleagues published a preprint of a randomised controlled trial that may be the most significant piece of cognitive health research in a generation — and it has received remarkably little mainstream attention.

The trial assigned 73 patients with mild cognitive impairment or early dementia to one of two groups: a personalised precision medicine protocol (addressing each individual’s specific contributors to cognitive decline — inflammation, insulin resistance, gut dysbiosis, hormonal insufficiency, nutrient deficiencies, sleep apnoea, toxin exposure) or standard of care. Over nine months, the results were striking.

The precision medicine group showed a 14-point improvement in overall neurocognitive function (from a mean of 92 to 106 — moving from impaired to normal range). The standard care group declined by 4.4 points. Executive function improved by nearly one standard deviation. Partner-reported cognitive symptoms improved significantly in the precision medicine group, while partners of standard-care patients reported continued decline.

The effect size was seven times greater than lecanemab — the leading approved Alzheimer’s drug — and four times greater than donanemab.

The epigenetic data was equally compelling. The OMICmAge mortality clock — one of the most sensitive biological ageing measures available — showed a reduction of approximately 1.3 years in the precision medicine group (p=0.016). Fourteen protocadherin genes involved in synaptic plasticity and neural circuit organisation were differentially methylated. Inflammatory markers — including TNFRSF17, EN-RAGE, and multiple cytokines — declined significantly.

What the Bredesen protocol treated was not a single pathway. It treated the whole system — simultaneously, personally, persistently.

The levers you have right now

The precision medicine protocol used in the Bredesen trial is complex, expensive, and requires clinical supervision. But most of its core components map directly onto accessible, food-first strategies. Here is where the overlap lies.

Homocysteine. The precision medicine group reduced homocysteine by 2.1 μmol/L. High homocysteine is both a marker of poor methylation and an independent risk factor for cognitive decline and dementia — it is directly neurotoxic at elevated levels. The methylation diet — rich in folate (leafy greens, legumes), B12 (oily fish, eggs), and B6 (chickpeas, bananas, poultry) — is the most direct dietary lever for reducing it.

Insulin resistance. HOMA-IR (a measure of insulin resistance) improved significantly in the precision medicine group; it worsened in the standard care group. Insulin resistance in the brain — sometimes called “type 3 diabetes” in the Alzheimer’s research literature — impairs glucose metabolism in neurons, reduces BDNF, and accelerates amyloid accumulation. Low glycaemic load eating, a 12-hour overnight fast, and regular movement all reduce it.

Vitamin D. The precision medicine group increased vitamin D by 20.5 ng/mL over nine months. The standard care group declined by 2.3 ng/mL. Vitamin D receptors are expressed throughout the brain; deficiency is associated with accelerated cognitive decline, neuroinflammation, and impaired clearance of amyloid. In the UK, supplementation is particularly important from October through April.

Sleep. Every patient in the trial was tested for sleep apnoea. This is not incidental — nocturnal hypoxemia is one of the most potent and under-recognised drivers of cognitive decline. The brain’s glymphatic system — which clears metabolic waste including amyloid — operates almost exclusively during deep sleep. Seven to eight hours of quality sleep is not optional for brain health; it is structural maintenance.

Gut health. All precision medicine patients received full stool analysis and gut healing protocols where dysbiosis or inflammation was found. The gut-brain axis is now central to cognitive health research — the vagus nerve, short-chain fatty acids, the tryptophan-serotonin pathway, neuroinflammatory signalling: all of these run through the gut. A fibre-rich, polyphenol-dense diet with regular fermented foods is the foundation.

The convergence: what both bodies of research are saying

The Harvard JAMA Neurology study and the Bredesen trial were developed from entirely different starting points. One is an observational epidemiological study of dietary patterns in healthy middle-aged adults. The other is a precision medicine RCT in patients with early dementia. They agree on almost everything.

Vegetables at scale. Oily fish. Legumes. Minimal processed meat. Polyphenols — berries, turmeric, garlic, dark chocolate, green tea. A 12-hour overnight fast. Quality sleep. Movement. Stress regulation. Gut health.

This is not a coincidence. These inputs address the same interconnected biological systems: methylation, inflammation, insulin sensitivity, the gut-brain axis, mitochondrial function, the antioxidant defence network. When you give these systems what they need consistently, in midlife, the outcomes show up decades later — in cognitive test scores, in brain volume, in epigenetic clock readings, in how clearly you think at seventy.

The window is open now. The research is consistent. The inputs are specific and accessible.

Supporting the brain alongside diet: Lion’s Mane

For those who want to add a targeted supplement layer to a brain-health dietary foundation, Hericium erinaceus — Lion’s Mane — is the most evidence-backed functional mushroom for cognitive support.

Its active compounds — hericenones from the fruiting body and erinacines from the mycelium — are the only naturally occurring compounds known to stimulate nerve growth factor (NGF) synthesis. NGF is essential for the growth, maintenance, and survival of neurons, including cholinergic neurons in the basal forebrain — the population most affected in early Alzheimer’s disease. NGF levels decline with age; compounds that support its synthesis are working directly at the biological level this research is concerned with.

Time Health’s formulation uses dual-extracted fruiting bodies — providing both the water-soluble beta-glucans (50% polysaccharides, 30% beta glucans) and the alcohol-soluble hericenones that single-extraction products often miss. GMP-certified, made in the UK, no fillers or binders.

What this means in practice

None of this requires a clinical protocol or a specialist consultation. It requires consistency, over years, with a relatively small number of evidence-backed habits.

Dark leafy greens every day. Oily fish two to three times a week. Legumes regularly. A 12-hour overnight fast most nights. Seven to eight hours of sleep, prioritised rather than negotiated away. Movement that raises your heart rate. Polyphenols — from food, ideally from seasonal food, because seasonal eating naturally rotates the compounds your cells are receiving.

These are not complicated. They are not expensive. They do not require willpower so much as they require understanding — understanding that the brain you will have at seventy is, in large part, being built right now.

That is both a responsibility and, when you sit with it, a genuinely hopeful piece of science.

If you want a structured framework for putting these habits into practice — the methylation diet, the 12-hour fast, sleep, movement, stress regulation, gut health — all seven are built into The Cellular Reset, an 8-week science-led programme designed specifically for women in perimenopause. It comes with a companion app that guides you through each habit, day by day.

This post references the Bredesen et al. precision medicine trial: Toups K et al., Preprints.org, December 2025, doi:10.20944/preprints202512.2694.v1. And the Harvard JAMA Neurology cohort study: Chen H et al., JAMA Neurol. 2026;83(4):382–391. The Bredesen study is a preprint and has not yet completed peer review.